Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05045963 · ClinicalTrials.gov registry record
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 232
- Enrollment target
- 1
- Study location
NCT05045963 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 232 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05045963, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 232 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently used to treat sepsis, but their clinical impact in hypotensive oncology patients upon the progression of sepsis is not known.
Conditions Studied
Interventions
- OTHER Electronic Health Record Review
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2026-02-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05045963
The ClinicalTrials.gov registry entry for NCT05045963 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (80% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Electronic Health Record Review is the first listed.
NCT05045963 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05045963 about?
NCT05045963 is a clinical study titled "Impact of Aminoglycosides in Hypotensive Septic Oncology Patients". This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently used to treat sepsis, b...
What is the current status of trial NCT05045963?
This trial is currently completed. The enrollment target is 232 participants. The study started on 2021-01-04. Estimated completion is 2026-02-13.
What conditions does trial NCT05045963 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Septicemia.
What interventions are being tested in trial NCT05045963?
The interventions under investigation include: Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05045963?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05045963 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.